STAT+: Rare disease advocates fume over FDA’s mixed signals
Stat News • 2/25/2026 – 2/26/2026
Summary
No summary yet.
Advertisement
Cluster Activity
1
1
2026-02-252026-02-26
Lindy Score Breakdown (V4.2)
3h
Age
1
Sources
from cluster
1
Hours Since Seen
Final Score12/100
CategoryAntiLindy
StatusActive
Recency Multiplier99% (0.5^1/48)
Hero EligibleYes
Story Timeline
- 2026-02-25
- 2026-02-26STAT+: Rare disease advocates fume over FDA’s mixed signals (current)
Score BreakdownRisk 70
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Same Story from 2 sources
Breaking Similar stories
STAT+: A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA
Stat News • Today
STAT+: FDA unveils rules for bespoke gene therapies, predicting flood of rare disease applications
Stat News • 2 days ago
STAT+: Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval
Stat News • 2 days ago
STAT+: Bayer sues J&J over ‘false and misleading claims’ about competing prostate cancer treatments
Stat News • 2 days ago
STAT+: Xenon’s seizure drug study reads out soon. Here’s what to expect
Stat News • Today
Group B Streptococcal Disease
NEJM • 1 day ago
Surgeon general nominee and senator face off over vaccines and ‘shared decision making’
Stat News • Today
Opinion: STAT+: Optum CMO: Doctors must take responsibility for patient outcomes
Stat News • 2 days ago
STAT+: How Mayo Clinic’s patients are helping Merck train its AI
Stat News • Today
STAT+: Pharmalittle: We’re reading about pharma lobbying, a disappointing Novo clinical trial, and much more
Stat News • 2 days ago